Tirzepatide denied for missing prior authorization by UnitedHealthcare?

Zepbound (obesity): BMI >=30 or >=27 with comorbidity. Mounjaro (T2DM): HbA1c >=7% despite metformin trial.

Step therapy: Document contraindications to required agents (phentermine: uncontrolled hypertension, cardiovascular disease, hyperthyroidism; topiramate: pregnancy risk, kidney stones, glaucoma; Contrave: uncontrolled hypertension, seizure disorder, eating disorders, opioid use). If prior trials exist, submit records showing 12+ week trial with inadequate response (<5% weight loss) or intolerable side effects. Clinical necessity: Cite FDA approval of Zepbound (tirzepatide) for chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidity (May 2023). Reference SURMOUNT-1 trial showing 15-21% weight loss vs 3% placebo. For patients with prediabetes or metabolic syndrome, emphasize cardiometabolic benefit and diabetes prevention (58% reduction in progression per DPP trial). Request expedited appeal if patient has failed/cannot tolerate step therapy agents due to medical contraindications.

UHC's prior-auth requirement on tirzepatide is universal in 2026 — there is no situation where Mounjaro or Zepbound bypasses PA on UHC commercial or Medicare Advantage Part D plans. When the denial reason is "prior auth required," the issue is that the PA either was never submitted, was submitted to the wrong channel, included incomplete documentation, or expired without renewal.

Resubmit through OptumRx's specific Mounjaro/Zepbound PA form (not a generic GLP-1 form — UHC distinguishes between the two indications). Required fields for approval:

Mounjaro (T2DM):

• HbA1c at most recent test (must be ≥7% per OptumRx criteria) with the lab date.
• Metformin trial with dose (target 2,000mg/day), duration (≥3 months), and tolerability documentation.
• If metformin contraindicated: cite eGFR (<30), lactic acidosis history, or documented severe GI intolerance at adequate dose with chart citation.
• Other diabetes medications tried (sulfonylurea, DPP-4 inhibitor, basal insulin, SGLT2 inhibitor) — not all required, but more documentation strengthens the PA.
• Specialist consultation if available — endocrinologist signature elevates the review.

Zepbound (obesity):

• BMI documented in past 12 months (≥30 or ≥27 with comorbidity) with the visit date.
• Comorbidity ICD-10 codes (E66.01 morbid obesity, I10 hypertension, E78.5 dyslipidemia, E11.9 T2DM, G47.33 OSA) — not narrative.
• 6-month lifestyle modification program with frequency (monthly visits with PCP, RD, or behavioral health), content (calorie target, exercise prescription, behavioral intervention), and progress (weight at each visit).
• Step therapy on phentermine/topiramate or Contrave with dates, doses, and outcomes — OR contraindication with chart citation.
• Continuation criterion if renewal: ≥5% weight loss at 6 months with explicit starting and current weight.

UHC's automated PA review uses strict checklist matching. Free-text justification rarely substitutes for a missing checkbox. If the form has a field, fill it with chart-documented evidence.

For tirzepatide PA renewals at 6 months, the dispositive criterion is the weight loss percentage (Zepbound) or HbA1c reduction (Mounjaro). If the response was inadequate, UHC will deny renewal regardless of how well the original PA was constructed. For Zepbound renewals showing 4% weight loss (just under the 5% threshold), the appeal can argue continuing improvement with projected ≥5% by month 7-8 — cite the specific trajectory.

The federal regulatory hook: 72-hour urgent appeal window under ERISA §503(f)(2)(i) if the patient is currently on the medication and PA renewal is delayed. Document the run-out date in the appeal to trigger urgent classification.

For Medicare Advantage members, 42 CFR §423.566 expedited timeline applies — UHC has 24 hours for expedited PA decisions, 72 hours for standard. If decision exceeds these timelines without a response, the PA is automatically approved by operation of regulation.

OptumRx procedural lever: submit PA through the OptumRx provider portal directly, not through pharmacy fax — fax submissions are processed slower and have higher denial rates due to OCR errors on chart documentation.

Closing tactical tip: if the patient is on existing tirzepatide therapy with PA expiring, request a 30-day bridge supply pending appeal under OptumRx's continuity-of-care policy. Without the bridge, the patient experiences a treatment gap that requires re-titration and disrupts response.